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Abstract
We summarize our recent work, using all atom molecular dynamics simulation to study the role of poly(ethylene
glycol) (PEG) in drug delivery. We have simulated the drug delivery liposome membrane, in both the Gel and Liquid
crystalline states. The simulations of the PEGylated membrane have been carried out in the presence of a physiolog-
ical concentration of NaCl, and two other salts encountered in physiological conditions, KCL and CaCl2. We also
simulated targeting moieties on the PEGylated membrane, comparing the behavior of two targeting moieties. We also
simulated PEG with three drug molecules for which it is used as a delivery aid: paclitaxel, piroxicam, and hematopor-
phyrin. We found that the speciﬁc properties of PEG, its solubility in both polar and non-polar solvents, and its acting
as a polymer electrolyte, have a signiﬁcant eﬀect on its behavior when used in drug delivery.
Keywords: poly(ethylene glycol), PEGylation, PEGylated liposomes, targeted drug delivery, nanomedicine, rational
drug design
PACS: 81.07.-b, 87.14.Cc, 87.15.ap, 87.85.Qr, 82.35.Jk, 82.35.Np
1. Introduction
The core of pharmaceutical research is drug design, the development of drug candidate molecules. Once a drug
molecule has been designed, it must be delivered intact to the location in the body where it is to perform its desired
function. Distribution of the drug to other areas of the body should be minimized, since this increases both the
necessary dose and unwanted side eﬀects. Thus, in designing a drug delivery mechanism there are two important
goals: targeting and protection.
Novel drug delivery mechanisms, that have seen success on both these fronts, is one of the most notable successes
of the application of nanotechnology to medicine, known as ”nanomedicine” [1, 2, 3]. The result, referred to as a
”nanovector” [1] or ”nanoscale delivery vehicle” [4], comes in several forms [5, 6], including liposomes, nanoparti-
cles, polymeric micelles, and dendrimers. These all have a common set of characteristics: 1) a diameter in the range
∼ 10 - 300 nm, 2) a core where the drug is encapsulated, 3) a protective layer that extends bloodstream lifetime,
often referred to as a ”stealth sheath” and 4) possibly targeting moieties on the exterior, to achieve targeted delivery.
This approach has already seen considerable success in many areas: cancer imaging and therapy [5, 6], combating
infectious agents [7], gene therapy [8], medical imaging [9, 10], and delivery of protein and peptide based drugs [11].
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The polymer, poly(ethylene-glycol) (PEG) has played an important role in drug delivery. It is the most commonly
used protective coating material for drug delivery liposomes (DDLs) [12] and nanoparticles [13], and has also provided
the same protection as a covalently bound conjugate to proteins [14], and other drug molecules [15]. The monomer
unit of PEG is O(CH2)2. Each monomer of PEG has both a polar oxygen atom, and a non-polar (CH2)2 group. PEG
is thus soluble in a wide variety of both polar and nonpolar solvents [16], and has also been widely employed as a
carrier for hydrophobic drug molecules to enhance their aqueous solubility or dissolution characteristics [17, 18, 19].
When PEG is used as the protective polymer coating for DDLs, the liposomes are said to be ”PEGylated”. A
liposome is composed of a phospholipid membrane formed into a vesicle, that can contain drug molecules. Liposomes
have been used in this capacity as far back as the 1970s [20]. The PEGylation of liposomes is achieved by adding
phospholipids with altered headgroups to the liposome formulation, the choline group replaced by an ethanolamine-
PEG. Typically the PEGylated lipids are included at a molar fraction of 5 to 10%, and the PEG lengths are in the range
of 1000 to 5000 daltons (∼ 20 to 110 monomers). Cholesterol, and sometimes sphyngomylin, are often included in the
membrane formulation for a tighter structure than a pure liquid crystalline membrane, while at the same time avoiding
the defects that occur in a gel membrane structure. In addition, liposomes that can be thermally driven to undergo a
transition from the gel to the liquid-crystalline state to achieve triggered release have been investigated [21].
As a protective polymer coating PEG is extremely successful. For example PEGylation increases the time DDLs
circulate in the bloodstream from ∼ 1 hour to the range of 1-2 days [22]. Considerable room for improvement,
however, remains; blood platelets, red blood cells, and some antibodies have a blood plasma circulation time in the
range of months. As outlined in the review paper of Knop et al. [23] several alternative polymers are currently under
investigation. Finding a superior alternative to PEG through a rational design approach will, however, require an
understanding of why PEG works as well as it does, and our current picture of this is unclear.
Clearly the PEG layer in some way impedes uptake by the reticuloendothelial system (RES) [24]. The ﬁrst step
of RES uptake is opsonization, where a set of bloodstream proteins adhere to the surface of foreign particles so that
they can be recognized by the macrophages that eliminate them. While the interaction between nanovectors and
bloodstream proteins has been the subject of many studies, the results are conﬂicted: while some studies indicate that
protein adhesion is inhibited by PEGylation [25], other studies have found no evidence of this [26]. Other proposed
mechanisms include acting as a direct steric barrier against macrophages and inhibition of liposome fusion [26].
Whatever the mechanism through which PEG increases bloodstream circulation, this will involve the structure of
PEG in the physiological environment, and its interaction, either with the drug molecule to which it is attached, or for
the case of when it is used as the protective sheath of a nanovector, the other elements of the nanovector surface. The
extent to which this can be studied experimentally is severely limited, and molecular dynamics simulation provides a
new window on this. In this manuscript we will review some of our recent work, using molecular dynamics simulation
to study the PEGylated liposome surface under a variety of conditions, its interaction with targeting ligands, and three
drug molecules with which PEG is combined in therapy: paclitaxel, piroxicam, and hematoporphyrin. This work is
covered in ﬁve manuscripts, four of which are already published [27, 28, 29, 30] and a ﬁfth in press [31].
2. Methods
2.1. Systems studied
As a model of the surface of the PEGylated liposome, we simulated a set of phospholipid membranes in periodic
boundary conditions, with all atom resolution. Since the diameter of DDLs is ∼ 100 nm, our model is eﬀective for the
same reason that a map is eﬀective. We studied membranes in both the gel and liquid crystalline states, through the use
of distearoyl (DS) and dilinoleoyl (DL) lipid tails respectively. This was in order to 1) model the two extremes of lipid
structure: observations in both systems are generally applicable to all lipid formulations that, as mentioned above,
have varying levels of cholesterol and 2) gain insight relevant to the properties of liposome based delivery systems
designed for triggered release through a transition from the gel to the liquid crystalline phase. Pure membranes with
phosphatidylcholine (PC) headgroups were simulated, along with membranes with PEG - phosphatidylethanolamine:
phosphatidylcholine (PE-PEG:PC) molar ratios of approximately 1:9 and 1:18. The systems were simulated with
NaCl at physiological concentration, and in the presence of two other salts encountered in physiological conditions:
KCl and CaCl2 at the same ionic strength for comparison. In addition simulations of membranes in both the liquid
crystalline and gel states were carried out with only the Na+ counterions for comparison. The counterions are needed
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since each PEGylated lipid has a net charge of -1. A recent assay of PEGylated liposomes with a novel targeting
moiety (AETP) has had a negative result. We simulated PEGylated membranes in both gel and liquid crystalline
states functionalized with both this moiety, and a moiety that has already been found to work, the RGD peptide, for
comparison. Simulations of PEG with three drugs with which it has been used in drug delivery: piroxicam, paclitaxel,
and hematoporphyrin, have also been made. For the case of hematoporphyrin, simulations were carried out with the
PEG both covalently bound, and unbound to the hematoporphyrin. For both the PEGylated membranes, and the drug
molecules with PEG, the PEG segment was 45 monomers long, known as PEG2000.
2.2. Simulation parameters
For all molecules and ions in our simulation the all-atom OPLS force ﬁeld [32] was used. A new all atom model for
PEG was built, and details of the construction and testing of this model, and all other details pertaining to force ﬁeld
implementation, can be found in our previous publications [27, 28, 29, 30], and references therein. Periodic boundary
conditions with the usual minimum image convention were used in all three directions. To preserve the covalent bond
lengths, the linear constraint solver (LINCS) algorithm [33] was used. The time step was set to 2 fs. The temperature
and pressure were controlled using the Nose´-Hoover [34, 35] and Parrinello-Rahman [36] methods respectively. The
temperatures of the solute and solvent were controlled independently. For pressure, we used a semi-isotropic control
for the membrane systems, and isotropic control for the PEG-drug molecule systems. The Lennard-Jones interactions
were cut oﬀ at 1.0 nm, and for the electrostatic interactions we employed the Particle Mesh Ewald (PME) method [37].
2.3. Analysis protocol
For the membrane systems ﬁve separate forms of analysis were performed on our simulated systems. First we
visualized the systems to obtain an intuitive picture of the systems. Next we determined the number, and location of
all the bound ions in each time step. Since ion binding is the most slowly relaxing variable regarding the properties we
intend to study, the convergence of the total number of bound ions was used to determine the eﬀective equilibration
time for each system. For all systems we simulated 100 ns or more beyond the equilibration time. The protocol used
to deﬁne bound ions is described in our previous publications [27, 28, 29, 30]. We then measured the mass density
proﬁle along the membrane normal for PEG, anions, cations, and phosphate headgroups for each system. After this we
measured the radial distribution function (RDF) between cation and headgroup oxygens, PEG oxygens, and anions.
Finally we measured the electrostatic potential along the membrane normal for each system. For the PEG - drug
systems we measured the distribution of the recorded values for the portion of the drug molecule covered by PEG, in
order to determine whether or not there is an eﬀective interaction between PEG and drug molecule.
3. Results
As shown in Fig. 1, the Na+ ions interacted strongly with the PEG oxygens, locating to the PEG layer, in addition
to the membrane headgroups. For the liquid crystalline membrane the PEG polymer was seen to penetrate into the
hydrophobic membrane interior (Fig. 1 C), however PEG did not enter the tighter structure of the gel membrane. We
compared the results for physiological salt concentration with the case of only counterions present. We found that
when the salt was added to the solvent, both the PEG layer expanded slightly and the Na+ ions distributed further out
into the PEG layer. As shown in Fig. 3, the strength of the association of the K+ ions with the PEG polymer was
weaker than that for the Na+ ions, and, more strikingly, there was no association observed between the Ca2+ ions and
the PEG. For both the gel membrane with PEG-PE:PC molar ratio of 1:18, shown in Fig. 3, and the liquid crystalline
membrane, shown in Fig. 1, The Cl− ions penetrated the PEG layer, but were excluded from the PEG layer of the gel
membrane with the molar ratio of 1:9. Our simulation of the PEGylated membranes functionalized with the AETP
moiety and RGD peptide, shown in Fig. 2, found that, as expected, the more hydrophobic AETP moiety was obscured
to a greater extent than the RGD peptide, thus providing a possible explanation for its failure. The AETP moiety,
however, did not penetrate into the membrane interior, for either the gel or liquid crystalline membrane, but rather was
covered by the PEG polymer itself. When we simulated the three drugs, paclitaxel, piroxicam, and hematoporphyrin
with PEG we found that there was no speciﬁc interaction between PEG and either piroxicam or paclitaxel. There was,
however, a strong attractive interaction between the hydrophobic center of the porphin ring of the hematoporphyrin
and the non-polar CH2 groups of the PEG, as shown in Fig. 4. For the case of PEG not bound covalently to the
 Alex Bunker /  Physics Procedia  34 ( 2012 )  24 – 33 27
hematoporphyrin we found this interaction was strengthened by the presence of a physiological salt concentration,
and this result was supported by absorbtion spectroscopy results.
 

Figure 1: PEGylated DLPC membrane, showing structuring of PEGylated membrane in the liquid crystalline phase. The membrane is shown a)
with only the ions opaque, b) all opaque, and c) the lipids transparent. We see that the Na+ ions, shown as blue, associate strongly with the PEG
polymers, and that the PEG lipid can penetrate into the lipid core, as highlighted in c). Our simulation with a DSPC membrane in the gel phase
showed that the tighter structure of the gel membrane precluded entry of PEG.
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Figure 2: DSPC membranes (gel state) in presence of a) NaCl, b) CaCl2, c) NaCl with PEGylated lipid molar density 1:18 instead of 1:9, and d)
KCl. Cl− ions are aquamarine, Na+ ions are blue, Ca2+ ions are gold, and K+ ions are pink. Note that, for the case of the membrane in CaCl2
solution, the Ca2+ cations do not associate with the PEG polymer.
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Figure 3: PEGylated DLPC membrane with the AETP targeting ligand attached. Membrane lipids shown as both opaque and transparent for clarity.
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Figure 4: Hematoporphyrin with covalently bound PEG. Note the attractive interaction between the lipophilic center of the hematoporphyrin and
the non-polar (CH2)2 groups. Association with a Na+ cation (seen in the ﬁgure, the Na+ shown as large blue sphere) has been found, both from our
simulation, and complementary experiment, to enhance this attractive interaction by increasing the exposure of the non-polar groups of the PEG.
4. Discussion and conclusion
4.1. Physical chemistry perspective
As discussed in the introduction, PEG is soluble in both polar and non-polar solvents, and these properties are
responsible for the behavior observed. Due to PEG being soluble in non-polar solvents in addition to water, it was
able to enter into the membrane core for the looser structure of the liquid crystalline membrane. The gel structure is
much tighter, thus presenting too great a free energy barrier to entry. This property of PEG also resulted in the PEG
polymer obscuring the more hydrophobic AETP targeting moiety to a greater extent than the more hydrophilic RGD
peptide. There was no evidence of any signiﬁcant contact between the AETP moiety and either the lipid headgroups
of the hydrophobic core of the membrane, for either the liquid crystalline or gel membranes. The AETP moieties
were obscured entirely by the PEG polymer. The attraction between PEG and hematoporphyrin is the result of an
eﬀective attraction between the non-polar CH2 groups of the PEG and the hydrophobic center of the porphin ring of
the hematoporphyrin (with polar water as solvent). The strengthening of this interaction in the presence of salt in
solution, that we observed, results from the following mechanism: the cations in the salt associate with the polar PEG
oxygens. This causes the PEG polymer to loop around them. This in turn preferentially exposes their non-polar CH2
groups to the exterior of the PEG, thus increasing the eﬀective hydrophobicity of PEG.
As discussed in the introduction, PEG is a polymer electrolyte and associates strongly with cations. Previous
simulations have observed the phenomenon of the PEG polymers looping around cations, for example the case of
PEG in solution with LiI as the salt [38]. The PEG chain has a natural curvature, that will ﬁt more comfortably around
one ion than another. It is known, as a result of this, to interact more strongly with Na+ than K+ ions [39]. Our result
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that PEG does not interact at all with Ca2+ is supported experimentally: Sondjaja et al. [40] found that the percentage
of free Ca2+ in solution varies linearly right down to zero concentration in presence PEO homopolymer.
The fact that the Cl− ions are excluded from the gel membrane with the 1:9 molar fraction of PEGylated lipids,
but able to colocate to the PEG layer in the liquid crystalline membrane and the gel membrane with the 1:18 molar
fraction of PEGylated lipids, is explained as follows: Cl− ions have a tightly bound water shell around them. When
the membrane is in the liquid crystalline phase there is both a much larger area per lipid and, as mentioned above,
a portion of the PEG polymers penetrates into the membrane core. Thus both the liquid crystalline membrane and
the membrane in the gel state with the 1:18 molar fraction of PEGylated lipids have a signiﬁcantly less dense PEG
layer. The decreased density of the PEG layer allows for water pockets between the PEG polymers large enough to
incorporate the Cl− ions with their water shells.
The result of the Na+ ions moving further out into the PEG layer in the presence of a physiological concentration
of salt is exactly the result one would expect from Poisson-Boltzmann theory. The slight increase in the thickness
of the PEG layer when salt is added to the solution results from the increased number of bound Na+ ions within the
PEG creating an increased internal repulsion. The same result has been observed in a polymeric micelle by Vukovic
et al. [41], in a study that combined simulation with experiment.
4.2. Pharmaceutical perspective
The PEG polymer is not a purely hydrophilic polymer. It is known to be soluble in both polar and non-polar
solvents [16]. This aﬀects its behavior, both in the PEGylated liposome, and when bound to drugs. This property of
PEG is already made use of, as PEG is widely employed as a carrier for hydrophobic drug molecules to enhance their
aqueous solubility or dissolution characteristics [17, 18, 19]. The results that can be attributed to this, 1) that PEG
can enter the liquid crystalline, but not gel, membrane, 2) the obscuring of the AETP moiety, and 3) the interaction
with the porphin ring of the hematoporphyrin that is strengthened by the presence of salt at physiological level, have
important consequences from a pharmaceutical perspective. PEG penetration into the lipid bilayer interior may eﬀect
the permeability of the membrane, possibly leading to premature drug leakage from the liposome. Some reports have
been published with results that indicate PEGylation can increase liposome permeability [42]. Liposomes, initially in
the gel state, that can be induced to undergo a phase transition to the liquid crystalline state, have been proposed as
a means of triggered release. The mechanism involves the defect structures that form during the phase transition that
result in a peak in membrane permeability [21]. We have shown evidence that the PEG polymer may enter into the
membrane interior at this time, and could clearly have an aﬀect on the nature of this transformation. If the cause of
the failure of the AETP moiety is the strengthened interaction with the PEG polymer resulting from its hydrophobic
nature, a possible remedy, that can be generally applied for all hydrophobic targeting moieties, can be proposed:
replacing PEG with a more hydrophilic polymer. Formulating PEGylated liposomes with only the polymer to which
the targeting ligand is attached being a diﬀerent polymer, more hydrophilic than PEG, is also possible.
The change in the nature of the PEG layer, from eﬀectively neutral to eﬀectively charged, with increasing PEG
density will result in an increase in the charge double layer at the surface. Since it is known that surface charge plays
a role in liposome uptake by the RES, this may be of pharmaceutical signiﬁcance. Surface charge on a foreign object
in the bloodstream is known to play a role in opsonization [24]. From our results it can be concluded that initially, at
low density, PEGylation forms a neutral layer at the liposome surface, decreasing the surface charge, however with
increasing PEG density this eﬀect is reversed, as the Cl− ions are expelled from the PEG layer, causing the PEG
layer to become eﬀectively positively charged again. This could explain the fact that, while some studies indicate that
protein adhesion is inhibited by PEGylation [25], other studies have found no evidence of this [26].
An alternate mechanism for the protective activity of PEG, that has been proposed, is inhibition of liposome
fusion [43]. Ions of Ca2+ are known to induce liposome fusion by cross-linking between lipid headgroups which are
known to strongly bind Ca2+ ions [44, 45, 46]. Holland et al. [47] found evidence that Ca2+ induced liposome fusion
is inhibited by PEGylation. Our result, that the PEG polymer does not interact with Ca2+ ions, provides a mechanism
for this: the Ca2+ ions will still bind to the lipid headgroups, however the PEG layers, that do not associate with the
Ca2+ ions, will act as a steric barrier to fusion.
4.3. Related work, and future possibilities
Unlike drug design, where the use of computational molecular modelling is well developed, the application of
molecular modeling in the design of drug delivery mechanisms is relatively new. With respect to the computa-
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tional modelling of PEGylated systems in the context of drug delivery, other work includes the modeling of poly-
meric micelles [41], PEGylated insulin [48], and course grained modeling of PEGylated membranes [49, 50] and
dendrimers [51]. A recent review by Huynh et al. [52] covers other recent computational research relevant to
nanomedicine. As far as we are aware no other research group has attempted to model the PEGylated liposome
surface with all atom resolution. Several of the properties that we have observed relied on the all atom resolution,
and have not been seen in course grained simulations of similar systems [49]. Thus molecular modeling with all atom
resolution has a clear role among the computational approaches to studying these systems.
The reason computational methods has seen greater development and use in drug design than in the design of
drug delivery mechanisms is the computational power required. Computational drug design, carried out using tech-
niques such as QSAR and ligand docking, can easily be conducted using desktop computers, in extreme cases running
overnight. The work discussed here represents several hundred thousand CPU hours of supercomputing resources,
run over the course of several months. With the availability of computational resources set to continue to increase
exponentially for the foreseeable future, we expect rational design through computational modeling, using the tech-
niques discussed here, will become as widespread in drug delivery mechanism design as it currently is in drug design.
As new polymer alternatives to PEG are developed, the same protocol that we used here with PEG can be used, and
their behavior can be directly compared to PEG. Studying more details of liposome formulation, and possibly direct
simulation of interaction with opsonin proteins are other possible avenues of computational research which may yield
relevant insight.
5. Acknowledgement
I would like to thank my many collaborators in the work reviewed in this manuscript, including Tomasz Ro´g,
Aniket Magarkar, Julia Lehtinen, Arto Urtti, Elina Vuorimaa, Marjo Yliperttula, Esra Karakas, Yen Chin-Li, Sami
Rissanen, Mariusz Kepczynski, Satu Hakola, Mathias Bergman, Marta Pasenkiewicz-Gierula, Reinis Danne, Adam
Orlowski, Mikko Karttunen, Oana Cramariuc, Sabir Mirza, Henri Xhaard and Magdalena Wytrwal. The computa-
tional research discussed in this manuscript was carried out using the resources of the Finnish IT Centre for Scientiﬁc
Computing (CSC).
[1] K. Riehemann, S. W. Schneider, T. A. Luger, B. Godin, M. Ferrari, H. Fuchs, Nanomedicine - challenge and perspectives, Angew. Chem. Int.
Ed. 48 (2009) 872 – 897.
[2] P. Debbage, Targeted drugs and nanomedicine: present and future, Curr. Pharm. Des. 15 (2009) 153 – 172.
[3] H. Boulaiz, P. J. Alvarez, A. Ramirez, J. A. Marchal, J. Prados, F. Rodrı´guez-Serrano, M. Pera´n, C. Melguizo, A. Aranega, Nanomedicine:
application areas and development prospects, Int. J. Mod. Sci. 12 (2011) 3303 – 3321.
[4] J. Shi, A. R. Votruba, O. C. Farokhzad, R. Langer, Nanotechnology in drug delivery and tissue engineering: from discovery to applications,
Nano Lett. 10 (2010) 3223 – 3230.
[5] R. Misra, S. Acharya, S. K. Sahoo, Cancer nanotechnology: application of nanotechnology in cancer therapy, Drug Discovery Today 15
(2010) 842 – 850.
[6] K. Loomis, K. McNeeley, R. V. Bellamkonda, Nanoparticles with targeting, triggered release, aid imaging functionality for cancer applica-
tions, Soft Matt. 7 (2011) 839 – 856.
[7] I. A. J. M. Bakker-Woudenberg, Long-circulating sterically stabilized liposomes as carriers of agents for treatment of infection or for imaging
infectious foci, Int. J Antimicrob. Agents 19 (2) (2002) 299 – 311.
[8] P. L. Felgner, G. M. Ringold, Cationic liposome-mediated transfection, Nature 337 (1989) 387 – 388.
[9] V. P. Torchilin, Liposomes as delivery agents for medical imaging, Mol. Med. Today 2 (6) (1996) 242 – 249.
[10] T. Lammers, S. Aime, W. E. Henninck, G. Storm, F. Kiessling, Theranostic nanomedicine, Acc. Chem. Res. 44 (10) (2011) 1029 – 1038.
[11] M. L. Tan, P. F. M. Choong, C. R. Dass, Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug
delivery, Peptides 31 (2010) 184 – 193.
[12] V. P. Torchilin, Recent advances with liposomes as pharmaceutical carriers, Nat. Rev. Drug. Discov. 4 (2) (2005) 145–160.
[13] J. C. Olivier, Drug transport to brain with targeted nanoparticles., NeuroRx 2 (1) (2005) 108–119.
[14] F. M. Veronese, G. Pasut, PEGylation for improving the eﬀectiveness of therapeutic biomolecules., Drugs Today 45 (9) (2009) 687–695.
[15] K. Nawalany, B. Kozik, M. Kepczynski, S. Zapotoczny, M. Kumorek, M. Nowakowska, B. Jachimska, Properties of polyethylene glycol
supported tetraaryporphyrin in aqueous solution and its interaction with liposomal membranes, J. Phys. Chem. B 112 (2008) 12231 – 12239.
[16] C. O¨. Dinc¸, G. Kibarer, A. Gu¨ner, Solubility proﬁles of poly(ethylene glycol)/solvent systems. II. comparison of thermodynamic parameters
from viscosity measurements, J. Appl. Polym. Sci. 117 (2010) 1100 – 1119.
[17] W. L. Chiou, S. Riegelman, Pharmaceutical applications of solid dispersion systems, J. Pharm. Sci. 60 (9) (1971) 1281 – 1302.
[18] A. T. M. Serajuddin, Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs, J.
Pharm. Sci. 88 (10) (1999) 1058 – 1066.
[19] C. Leuner, J. Dressman, Improving drug solubility for oral delivery using solid dispersions, Eur. J. Pharm. Biopharm. 50 (2000) 47 – 60.
[20] D. D. Lasic, Novel applications of liposomes, Trends Biotechnol. 16 (7) (1998) 307 – 321.
 Alex Bunker /  Physics Procedia  34 ( 2012 )  24 – 33 33
[21] L. Paasonen, B. Romberg, G. Storm, M. Yliperttula, A. Urtti, W. E. Hennink, Temperature-sensitive poly(N-(2-
hydroxypropyl)methacrylamide mono/dilactate)-coated liposomes for triggered contents release, Bioconj. Chem. 18 (2007) 2131 –
2136.
[22] S. M. Moghimi, J. Szebeni, Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and
protein-binding properties, Prog. Lipid Res. 42 (6) (2003) 463–478.
[23] K. Knop, R. Hoogenboom, D. Fischer, U. Schubert, Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives,
Angew. Chem. Int. Ed. 49 (2010) 6288 – 6308.
[24] X. Yan, G. L. Scherphof, J. A. A. M. Kamps, Liposome opsonization, J. Liposome Res. 15 (2005) 109 – 139.
[25] H. Du, P. Chandaroy, S. W. Hui, Grafted poly-(ethylene glycol) on lipid surfaces inhibits protein adsorption and cell adhesion, Biochim.
Biophys. Acta 1326 (1997) 236 – 248.
[26] M. E. Price, R. M. Cornelius, J. L. Brash, Protein adsorption to polyethylene glycol modiﬁed liposomes from ﬁbrinogen solution and from
plasma, Biochim. Biophys. Acta 1512 (2001) 191 – 205.
[27] M. Stepniewski, A. Bunker, M. Pasenkiewicz-Gierula, M. Karttunen, T. Ro´g, Eﬀects of the lipid bilayer phase state on the water membrane
interface, J. Phys. Chem. B 114 (2010) 11784 – 11792.
[28] M. Stepniewski, M. Pasenkiewicz-Gierula, T. Ro´g, R. Danne, A. Orlowski, M. Karttunen, A. Urtti, M. Yliperttula, E. Vuorimaa, A. Bunker,
Study of PEGylated lipid layers as a model for PEGylated liposome surfaces: molecular dynamics simulation and langmuir monolayer
studies, Langmuir 27 (12) (2011) 7788 – 7798.
[29] J. Lehtinen, A. Magarkar, M. Stepniewski, S. Hakola, M. Bergman, T. Ro´g, M. Yliperttula, A. Urtti, A. Bunker, Analysis of cause of failure
of new targeting peptide in PEGylated liposome: molecular modeling as rational design tool for nanomedicine, Eur. J. Pharm. Sci. 46 (3)
(2012) 121 – 130.
[30] A. Magarkar, E. Karakas, M. Stepniewski, T. Ro´g, A. Bunker, Molecular dynamics simulation of pegylated bilayer interacting with salt ions:
a model of the liposome surface in the bloodstream, J. Phys. Chem. B 116 (14) (2012) 4212 – 4219.
[31] Y.-C. Li, S. Rissanen, M. Stepniewski, O. Cramariuc, T. Ro´g, S. Mirza, H. Xhaard, M. Wytrwal, M. Kepczynski, A. Bunker, Study of
interaction between peg carrier and 3 relevant drug molecules: piroxicam, paclitaxel, and hematoporphyrin, J. Phys. Chem. B in press.
[32] W. L. Jorgensen, J. Tirado-Rives, The OPLS potential functions for proteins. energy minimizations for crystals of cyclic peptides and crambin,
J. Am. Chem. Soc. 110 (1988) 1657 – 1666.
[33] B. Hess, H. Bekker, H. J. C. Berendsen, J. G. E. M. Fraaije, LINCS: A linear constraint solver for molecular simulations, J. Comp. Chem.
18 (12) (1997) 1463 – 1472.
[34] S. Nose´, A uniﬁed formulation of the constant temperature molecular dynamics methods, J. Chem. Phys. 81 (1) (1984) 511 – 519.
[35] W. G. Hoover, Canonical dynamics: Equilibrium phase-space distributions, Phys. Rev. A 31 (3) (1985) 1695 – 1697.
[36] M. Parrinello, A. Rahman, Polymorphic transitions in single crystals: A new molecular dynamics method, J. Appl. Phys. 52 (12) (1981) 7182
– 7190.
[37] U. Essman, L. Perela, M. L. Berkowitz, T. Darden, H. Lee, L. G. Pedersen, A smooth particle mesh Ewald method, J. Chem. Phys. 103 (1995)
8577 – 8593.
[38] D. Diddens, A. Heuer, O. Borodin, Understanding the lithium transport within a rouse-based model for a PEO/LiTFSI polymer electrolyte,
Macromolecules 43 (2010) 2028 – 2036.
[39] P. Johansson, S. P. Gejji, J. Tegenfeldt, J. Lindgren, Local coordination and conformation in polyether electrolytes: geometries of M-triglyme
complexes (A4 = Li, Na, K, Mg and Ca) from ab-initio molecular orbital calculations, Solid State Ionics 86 – 88 (1996) 297 – 302.
[40] H. R. Sondjaja, T. A. Hatton, K. C. Tam, Self-assembly of poly(ethylene oxide)-block-poly(acrylic acid) induced by CaCl2: mechanistic
study, Lamgmuir 24 (2008) 8501 – 8506.
[41] L. Vukovic´, F. A. Katib, S. P. Drake, A. Madriga, K. S. Brandenburg, P. Kra´l, H. Onyuksel, Structure and dynamics of highly PEG-ylated
sterically stabilized micelles in aqueous media, JACS 133 (2011) 13481 – 13488.
[42] A. R. Nicholas, M. J. Scott, N. I. Kennedy, M. N. Jones, Eﬀect of grafted polyethylene glycol (PEG) on the size, encapsulation eﬃciency and
permeability of vesicles, Biochim. Biophys. Acta 1463 (2000) 167 – 178.
[43] N. D. Santos, C. Allen, A.-M. Doppen, M. Anantha, K. A. K. Cox, R. C. Gallagher, G. Karlsson, K. Edwards, G. Kenner, L. Samuels,
M. S. Webb, M. B. Bally, Inﬂuence of poly(ethylene glycol) grafting density and polymer length on liposomes: Relating plasma circulation
lifetimes to protein binding, Biochim. Biophys. Acta 1768 (2007) 1367 – 1377.
[44] S. Po¨yry, T. Ro´g, M. Karttunen, I. Vattulainen, Mitochondrial membranes with mono- and divalent salt: Changes induced by salt ions on
structure and dynamics, J. Phys. Chem. B 113 (2009) 15513 – 15521.
[45] Z. K. Issa, C. W. Manke, B. P. Jena, J. J. Potoﬀ, Ca2+ bridging of apposed phospholipid bilayers, J. Phys. Chem. B 114 (2010) 13249 – 13254.
[46] X. L. R. Iraolagoitia, M. F. Martini, Ca2+ adsorption to lipid membranes and the eﬀect of cholesterol in their composition, Colloids Surf., B
76 (2010) 215 – 220.
[47] J. W. Holland, C. Hui, P. R. Cullis, T. D. Madden, Poly(ethylene glycol)-lipid conjugates regulate the calcium-induced fusion of liposomes
composed of phosphatidylethanolamine and phosphatidylserine, Biochemistry 35 (1996) 2618 – 2624.
[48] C. Yang, D. Lu, Z. Liu, How PEGylation enhances the stability and potency of insulin: a molecular dynamics simulation, Biochemistry 50
(2011) 2585 – 2593.
[49] S.-C. Yang, R. Faller, Pressure and surface tension control self-assembled structures in mixtures of pegylated and non-pegylated lipids,
Langmuir 28 (2012) 2275 – 2280.
[50] F. M. Thakkar, K. G. Ayappa, Eﬀect of polymer grafting on the bilayer gel to liquid-crystalline transition, J. Phys. Chem. B 114 (2010) 2738
– 2748.
[51] H. Lee, R. G. Larson, Eﬀects of PEGylation on the size and internal structure of dendrimers: self-penetration of long PEG chains into the
dendrimer core, Macromolecules 44 (7) (2011) 2291 – 2298.
[52] L. Huynh, C. Neale, R. Pome`s, C. Allen, Computational approaches to the rational design of nanoemulsions, polymeric micelles, and
dendrimers for drug delivery, Nanomed. Nanotechnol. Biol. Med. 8 (2012) 20 – 36.
